Vaxart, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $237.3M | $28.7M | $7.4M | $107.0K | $892.0K | $4.0M | $9.9M | $4.2M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $201.6M | $74.2M | $68.1M | $81.1M | $48.7M | $19.9M | $14.5M | $17.3M |
| SG&A Expense | $17.6M | $20.8M | $22.6M | $29.4M | $21.9M | $15.2M | $6.2M | $6.7M |
| Operating Income | $18.1M | $-66.3M | $-83.3M | $-114.6M | $-72.8M | $-30.2M | $-15.8M | $-21.8M |
| Operating Margin | 7.6% | -231.0% | -1,129.5% | -107,090.7% | -8,156.1% | -745.7% | -160.1% | -523.1% |
| Interest Expense | — | — | — | — | $0 | $0 | $315.0K | $821.0K |
| Pretax Income | $16.8M | $-66.7M | $-82.2M | $-107.7M | $-70.4M | $-32.0M | $-18.2M | $-17.9M |
| Income Tax Expense | $476.0K | $260.0K | $261.0K | $67.0K | $107.0K | $238.0K | $490.0K | $109.0K |
| Net Income | $16.3M | $-66.9M | $-82.5M | $-107.8M | $-70.5M | $-32.2M | $-18.6M | $-18.0M |
| Net Margin | 6.9% | -233.3% | -1,117.6% | -100,708.4% | -7,900.2% | -796.3% | -189.1% | -433.0% |
| EPS (Basic) | $0.07 | $-0.33 | $-0.57 | $-0.84 | $-0.58 | $-0.36 | $-0.86 | $-2.90 |
| EPS (Diluted) | $0.07 | $-0.33 | — | — | $-0.58 | $-0.36 | $-0.86 | $-2.90 |
| Shares Outstanding (Basic) | 230.3M | 202.1M | 144.8M | 127.7M | 121.5M | 110.3M | 48.3M | 7.1M |
| Shares Outstanding (Diluted) | 230.3M | 202.1M | 144.8M | 127.7M | 121.5M | 110.3M | 48.3M | 7.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |